ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B.
 PMID: 24160943       2013       Virology journal
Abstract: while the HBV rtM204V mutations was significantly associated with HBV rtL180M mutations [rtM204V+rtL180M (100%, 33/33) vs. rtM204I+rtL180M (60.9%, 39/64), P<0.001].
Result: Among those rtM204 mutations, a total of 14 types of rtM204 containing mutant patterns were observed, and rtM204I/V+rtL180M (78/106, 73.6%) and


  Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and Sao Paulo, Brazil.
 PMID: 24165277       2013       Virology journal
Result: Modifications within the POL gene were observed in 9 out of 34 samples (26.47%); we found only one case with the rtM204V mutation, which caused complete resistance to LAM, along with the compensatory mutation rtL180M (2.94%).
Result: When the genes were analyzed together, 9 of the 34 samples had mutations in both genes, and we found the following combinations: sM133L + sI195T with rtL80F + rtT128P, sI195M with rt PMID: 24175847       2013       Asian Pacific journal of cancer prevention
Abstract: Six of the the mutated samples (14.6%) having rtL180M missense transversion mutation and resistance to combined adefovir and lamivudin.
Abstract: The current results provide evidence that rtL180M and rtM204V/I/A mutations of HBV-DNA may be associated with a poor antiviral response and HBV chronicity during conventional therapy in Turkish patients.


  [Investigation of baseline antiviral resistance in treatment-naive chronic hepatitis B cases].
 PMID: 24237431       2013       Mikrobiyoloji bulteni
Abstract: Mutations conferring resistance to entecavir + lamivudine (S202G, M204V, L180M, T184N) were identified in one patient whereas L180P, A181Q and A194V substitutions associated with probable lamivudin + adefovir and tenofovir resistance, respectively, were detected in other patients.


  Substitution rtq267h of hepatitis B virus increases the weight of replication and Lamivudine resistance.
 PMID: 24348637       2013       Hepatitis monthly
Figure: Huh7 cells were transfected with pHBV1.3 (Figure 3 A), -rtQ267H (Figure 3 B), -rtM204V/Q267H (Figure 3 C), -rtL180M/M204V (Figure 3 D), -rtL180M/M204V/Q267H (Figure 3 E), and then treated with LMV at the indicated concentrations.
Figure: Huh7 cells were transfected with pHBV1.3, -rtQ267H, -rtM204V/Q267H, -rtL180M/


  Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
 PMID: 21777282       2012       Journal of gastroenterology and hepatology
Abstract: CONCLUSIONS: The rtL180M mutation of HBV, as well as a small decrease in HBV-DNA after 1 year of treatment might be closely associated with frequent occurrence of virological resistance to ADV in patients with LAM-resistant CHB.
Abstract: However, interestingly, patients carrying rtL180M experienced VB during ADV monotherapy more frequently than those not carrying rtL180M (2-year cumulative probability of VB: 37% vs 3% at 2 years, P < 0.01).
Abstract: On multivariate Cox proportional hazards analysis, rtL180M (hazard ratio [HR]: 8.62, 95% confidence interval: 1.08-69.09, P = 0.042) and decrease in HBV-DNA for 1 year of treatment (HR: 0.69, 95


  Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico.
 PMID: 22166560       2012       Annals of hepatology
Abstract: As well, rtM204V and rtL180M mutations are common in HBV-HIV co-infected patients with genotype G and ART experience.


  Pre-existing YMDD mutants in treatment-naive patients with chronic hepatitis B are not selected during lamivudine therapy.
 PMID: 22170540       2012       Journal of medical virology
Abstract: DPO-based multiplex PCR showed two YMDD mutations in two patients before LAM therapy; rtM204V and rtL180M + rtM204V/I.
Abstract: Further, two patients had an rtL180M mutation without an accompanying rtM204V/I mutation.


  Risk factors of gene-resistant mutations in different nucleosides.
 PMID: 22260834       2012       Hepato-gastroenterology
Abstract: In LAM group, rtL180M combined with rtM204V mutations accounted for 32.7% and in ADV group, rtN236T mutation accounted for 12.3%.


  Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.
 PMID: 22314422       2012       Journal of hepatology
Abstract: METHODS: HBV-resistant mutants (rtL180M+M204V, rtV173L+L180M+M204V, rtM204I, rtL180M+M204I, rtN236T, rtA181V, rtA181V+rtN236T, rtA181T+N236T, and rt



Browser Board

 Co-occurred Entities




   Filtrator